DCB Versus Primary Selective Stenting in TASC C/D Femoropopliteal Artery Disease

Inclusion Criteria: * Subject age 18-85yrs. * Subject has been informed of the nature of the study, agrees to participate, and has signed a Medical Ethics Committee approved consent form. * Subject understands the duration of the study, agrees to attend follow-up visits, and agrees to complete the required testing. * Rutherford category 2-5. * Subject has a de novo TASC C/D femoropopliteal artery lesions which does not exceed to the segment P1 of popliteal artery. * The total length of target lesion ≤30cm. * Reference vessel diameter \>4 mm and \<6.5 mm by visual assessment. * Patent inflow artery with stenosis \<30% and at least 1 infrapopliteal artery to the ankle (\<50% diameter stenosis). * A guidewire has successfully traversed the target treatment segment. Exclusion Criteria: * Acute thrombus in the target vessels. * Vessel stenosis or occlusion due to Buerger's disease or autoimmune arteritis. * Subject received prior stents implantation with in-stent restenosis or occlusion. * Reintervention of the target lesion \<90 days before the study procedure. * Acquired thrombophilia or uncontrolled hypercoagulation states. * Life expectancy \<12 months. * Severe renal（SCr≥2.5 mg/dl）or hemodialysis dependence. * Pregnancy, suspected pregnancy, or breastfeeding during study period. * Contraindication to contrast media or any study-required medication (antiplatelet, anticoagulant, or thrombolytic agents, etc.). * Hypersensitivity to nitinol and/or paclitaxel.